A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer.
Fiche publication
Date publication
novembre 2023
Journal
BMC cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BERTAUT Aurélie, Pr GHIRINGHELLI François, Dr MARTIN Etienne, Dr MIRJOLET Céline, Pr TRUC Gilles, Dr HERVIEU Alice, Dr QUIVRIN Magali, Dr LIMAGNE Emeric, Dr FUMET Jean-David, Dr HENNEQUIN Audrey, Dr ZANETTA Sylvie, Dr THIBAUDIN Marion, Dr ROUFFIAC-THOUANT Magali, Dr VULQUIN Noémie
Tous les auteurs :
Roussot N, Fumet JD, Limagne E, Thibaudin M, Hervieu A, Hennequin A, Zanetta S, Dalens L, Fourrier T, Galland L, Jacob P, Bertaut A, Rederstorff E, Chevalier C, Ghirardi S, Gilbert E, Khoukaz A, Martin E, Nicolet C, Quivrin M, Thibouw D, Vulquin N, Truc G, Rouffiac M, Ghiringhelli F, Mirjolet C
Lien Pubmed
Résumé
Immunotherapy targeting the PD-1/PD-L1 pathway is a standard of care in a number of metastatic malignancies, but less than a fifth of patients are expected to respond to ICIs (Immune Checkpoint Inhibitors). In a clinical trial, combining the anti-TIGIT (T cell immunoreceptor with Ig and ITIM domains) Mab (monoclonal antibody) tiragolumab with atezolizumab improved outcomes in non-small cell lung cancer. In preclinical models, SBRT (Stereotactic Body Radiation Therapy) could increase expression levels of the inhibitory co-receptors TIGIT and PD-L1. We aim to assess the combination of tiragolumab with atezolizumab and SBRT in metastatic, previously treated by ICIs, non-small cell lung cancer, head and neck cancer, bladder cancer, and renal cell cancer.
Mots clés
Atezolizumab, Bladder cancer, Head and neck cancer, Immunotherapy, Non-small cell lung cancer, PDL-1, Renal cell cancer, SBRT, Stereotactic body radiation therapy, TIGIT, Tiragolumab
Référence
BMC Cancer. 2023 11 9;23(1):1080